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Abstract
Background: Designing small-molecule kinase inhibitors with desirable selectivity profiles is a
major challenge in drug discovery. A high-throughput screen for inhibitors of a given kinase will
typically yield many compounds that inhibit more than one kinase. A series of chemical
modifications are usually required before a compound exhibits an acceptable selectivity profile.
Rationalizing the selectivity profile for a small-molecule inhibitor in terms of the specificity-
determining kinase residues for that molecule can be an important step toward the goal of
developing selective kinase inhibitors.
Results: Here we describe S-Filter, a method that combines sequence and structural information
to predict specificity-determining residues for a small molecule and its kinase selectivity profile.
Analysis was performed on seven selective kinase inhibitors where a structural basis for selectivity
is known. S-Filter correctly predicts specificity determinants that were described by independent
groups. S-Filter also predicts a number of novel specificity determinants that can often be justified
by further structural comparison.
Conclusion:  S-Filter is a valuable tool for analyzing kinase selectivity profiles. The method
identifies potential specificity determinants that are not readily apparent, and provokes further
investigation at the structural level.
Background
The human genome contains approximately 500 protein
kinases that regulate numerous cellular processes via pro-
tein phosphorylation [1]. Protein kinases mediate cell sig-
naling pathways that are important for metabolism,
development, apoptosis, immune responses, cell prolifer-
ation, and differentiation. Several of these pathways have
been implicated in cancer, inflammation, and metabolic
diseases. Thus, a number of protein kinases have been
proposed as drug targets for these diseases [2]. Designing
selective kinase inhibitors is a major challenge in drug dis-
covery and development. The gene family is large and
most kinases domains are similar in sequence and struc-
ture. The selectivity issues associated with small molecules
that bind to the ATP catalytic binding site are particularly
challenging as most kinases have the same active-site
chemistry.
Understanding the basis of kinase inhibitor selectivity is
crucial to the design of safe and efficacious drugs. Ideally,
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a drug will inhibit a small set of kinases that are relevant
to the disease while avoiding the inhibition of kinases that
may lead to toxic side effects. For example, imatinib
inhibits a number of kinases that are believed to be
important for certain cancer types [3]. However, most
kinase-targeted drugs exhibit one or more toxic side effects
that may include skin rash, gastrointestinal perforation,
diarrhea, vomiting, cardiotoxicity, and bleeding [4,5]. To
avoid potential toxic side effects, most kinase drug discov-
ery projects assess the selectivity of their small molecules
against a panel of kinases. Typically, drug discovery teams
follow up on lead compounds that inhibit a small
number of kinases with the goal of further optimizing
selectivity along with other pharmacokinetic properties.
There are at least two major challenges associated with
selectivity optimization: 1) understanding the basis for
the measured selectivity profile and how it might be
improved, and 2) extrapolating from the measured profile
to the rest of the kinome as complete selectivity data are
rarely available. Although this work is primarily con-
cerned with first task, the two problems are not always
considered separately. Indeed, several studies have
focused on variations of these two problems by exploring
relationships between sequence, structure and small mol-
ecule selectivity [6-10]. Vulpetti et al identified the most
variable residues in the ATP binding site as good interac-
tion sites for specific inhibitors. It was shown that kinases
with less than 60% sequence identity are poorly correlated
with SAR similarity [6,7]. In contrast, kinases with greater
than 60% identity have a good chance of being inhibited
by the same set of compounds.
Unfortunately, these observations do not translate into
accurate prediction of kinase off-targets, i.e., those kinases
other than the intended kinase that are inhibited. Shein-
erman et al [8] also evaluated sequence identity as a pre-
dictor of kinase off-targets. For example, when the kinase
off-targets for a given inhibitor are predicted to be those
for which fewer than seven binding site residues are non-
identical, only half of genuine off-targets were predicted
correctly [8]. The sensitivity (i.e. the number of correctly
predicted off-targets divided by the total number of
known off-targets) of this prediction was improved to
0.69 by setting the threshold to eleven non-identical bind-
ing site residues. However, this was detrimental to the spe-
cificity of the prediction, as less than half of non-targets
were correctly predicted as non-targets. By restricting anal-
yses to energetically important binding site residues,
Sheinerman et al were able to improve the sensitivity and
specificity of off-target predictions.
Following these studies, we hypothesized that metrics
such as sequence identity may be too general to explain
selectivity data. For example, p38α, p38β, p38γ, and p38δ
all belong to the same subfamily and their binding sites
are very similar in sequence. However, a single residue dif-
ference (Met to Thr) appears to be sufficient for some
compounds to distinguish p38α and p38β from p38γ and
p38δ [11]. Furthermore, more distantly related kinases
(e.g. NLK and GAK) that have the same specificity deter-
mining threonine are also inhibited by the same com-
pound [12]. This suggests that single-residue differences
need to be considered independently when attempting to
explain kinase selectivity.
It is also clear that kinase selectivity needs to be rational-
ized in the context of three-dimensional co-crystal struc-
tures. Although structures are not available for every
kinase, it is common to dock a compound from a solved
X-ray structure to other superposed kinase structures. The
docking procedure can be performed manually or with
the aid of standard docking and energy minimizing pro-
grams [13]. Rationalizing selectivity across multiple
docked kinase structures requires careful assessment of
the docked poses. Proposed steric clashes may point to a
bona fide selectivity determining residue or an erroneous
kinase – small molecule conformation.
Recognizing the limitations of sequence identity as a pre-
dictor of kinase off-targets and the need to consider struc-
tural information, we have developed a complementary
approach known as S-Filter. S-Filter relies on structural
and sequence information to predict specificity determi-
nants for a particular kinase inhibition profile. It is
intended as a hypothesis generation tool that will prompt
further investigation at the structural level. Here, we
describe S-Filter and its application to kinase selectivity
data.
Results
A novel method called S-Filter was developed to predict
specificity-determining residues for kinase inhibitors. The
method is based on the assumption that a compound's
affinity for one set of kinases over another set of kinases is
due to the presence of residues that either permit or pre-
vent binding, respectively. Intuitively, we expect a specifi-
city determinant to be one or more residues that are
primarily found in the set of inhibited kinases. It also
seems reasonable to assume that the set of inhibited
kinases will have identical or very similar residues at the
site of specificity. That is, the specificity determinants will
be conserved in sequence across the inhibited kinases.
Furthermore, specific compounds often fill a small cavity
that is unique to the set of inhibited kinases. Kinases that
have a bulkier residue at the corresponding position will
not have a cavity that can be occupied by the compound.
Instead, the compound will clash with the bulkier residue,
thus preventing potent inhibition. This suggests that spe-
cificity determinants will often be relatively small resi-BMC Bioinformatics 2008, 9:491 http://www.biomedcentral.com/1471-2105/9/491
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dues. Of course, the presence of a bulkier residue does
always lead to an unfavorable steric clash. A large residue
can often adopt a different conformation that accommo-
dates the compound. However, a large residue is less likely
to accommodate a compound when it is buried deep in
the confines of the active site pocket where there is little
room to maneuver. This suggests that specificity determin-
ing-residues will often have low solvent accessibility.
We therefore consider four key questions when predicting
specificity-determining residues: 1) How specific is the
binding site residue to the set of inhibited kinases? 2) Is
the residue deep in the pocket where steric clashes are less
likely to be avoided? 3) Is the residue small and likely to
create a sub-pocket that is unique to the set of inhibited
kinases? 4) Is the residue conserved in sequence among
the set of inhibited kinases? These four parameters are
quantified by the N-score, SA-score, MW-score, and C-
score respectively. Each of these terms contributes to a Fil-
ter-score and are described in more detail below.
Residue Filters
Before we explain the finer details of S-Filter, it is neces-
sary to describe how a residue filter behaves in PFAAT
[14]. A reside filter allows one to only view sequences that
have a particular residue at an alignment column. For
example, one can imagine applying an alanine filter to
column 10 of a kinase multiple sequence alignment. As a
result, all kinase sequences that lacked an alanine at col-
umn 10 would not be displayed in the alignment; the vis-
ible kinase sequences would all have an alanine at column
10. If the set of visible kinases are potently inhibited by a
small molecule, and the set of hidden kinases are not
inhibited by the same small molecule, we have also
applied a potential selectivity filter at column 10. In other
words, a selectivity filter is a residue filter that is applied
to a specificity determining residue.
S-Filter
Given a set of alignment columns that correspond to a
small-molecule binding site, S-Filter attempts to identify
the set of alignment columns that best explain an inhibi-
tion profile. To do this, S-Filter identifies a subset of resi-
dues that can act as a potential filter for the low-affinity
kinases. S-Filter applies residue filters to one or more
alignment columns until the set of uninhibited kinases
are hidden from the display and only potently inhibited
kinases remain visible. S-Filter typically applies filters to
alignment columns that have residue(s) which distin-
guish the high-affinity kinases from the low-affinity
kinases.
For example, the high affinity kinases may have a glycine
at an alignment position where the low-affinity kinases
have other residue types. By applying a filter for glycine,
the set of uninhibited kinases would be filtered out. Thus,
the set of applied filters are predicted as specificity-deter-
mining residues, as their combination will only be found
in the kinases that bind the compound with high affinity.
The order in which residue filters are applied to alignment
columns is determined by a Filter-score that is described
below. To ensure that all the inhibited kinases remain vis-
ible, a residue filter must specify those residues that are
present in the set of inhibited kinases. Obviously, a resi-
due filter will have maximum effect when none of these
residues are present in the set of uninhibited kinases.
S-Filter is implemented in PFAAT [14], a Java application
which provides an interface to analyze and annotate mul-
tiple sequence alignments. S-Filter requires a selectivity
profile for the compound of interest, a solved three-
dimensional structure of the compound in complex with
a kinase, and a multiple sequence alignment of the
kinases in the selectivity profile. The selectivity data
described below was loaded into PFAAT as sequence
annotations. A threshold of 75% was set to distinguish the
set of inhibited kinases from the set of uninhibited
kinases. An exception was made for PHA-00781089,
which inhibits MK2 at 70%.
Filter-score
S-Filter computes a Filter-score for each binding site col-
umn in the multiple sequence alignment, and applies the
residue filter to the highest scoring column. A high scoring
Filter-score implies the column has one or all of the fol-
lowing: 1) A set of residues that are unique to the set of
inhibited kinases as specified by the N-score, 2) A residue
that is buried deep in the reference protein structure as
specified by the SA-score. 3) Small residues within the set
of inhibited kinases as specified by the MW-score. 4) A set
of residues which are either identical or very similar
among the set of inhibited kinases as specified by the C-
score.
The filtering process is iterated until all uninhibited
kinases are filtered out, or all possible columns have had
a filter applied. The Filter-score for a given column is the
product of the following terms:
Filter-score = N-score × SA-score × MW-score × C-score
The Filter-score is a simple heuristic that attempts to incor-
porate some of our basic assumptions and understanding
of small molecule specificity. It does not attempt to incor-
porate other structural features that cannot be computed
for every kinase in the selectivity panel.BMC Bioinformatics 2008, 9:491 http://www.biomedcentral.com/1471-2105/9/491
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N-score
Residues that are unique to the set of inhibited residues
are potential selectivity determinants. The objective of the
N-score is to identify residues that are unique to the set of
inhibited kinases. Therefore, S-Filter counts the number of
kinases (N-score) below the inhibition threshold that do
not have any of the residues that exist in the set of inhib-
ited kinases. It is designed to place greater weight on align-
ment columns where the set of inhibited kinases have
residues that are absent or rarely possessed by the set of
uninhibited kinases. For example, if a compound inhibits
two of the twenty seven kinases in our selectivity panel, a
maximum N-score of twenty five would indicate that
none of the uninhibited kinases possess the same residues
that belong to the two inhibited kinases. Invariant bind-
ing site columns will be assigned a minimum N-score of
zero as the set of uninhibited kinases will be identical to
the set of inhibited kinases. For example, the glutamate in
α helix C is identical across our panel of kinases and it is
unlikely that it is directly involved in determining specifi-
city for a small molecule.
SA-score
Residues with low solvent accessibility are likely to be
deep in the pocket and will often make significant interac-
tions with the small molecule. Importantly, residues with
low solvent accessibility are less likely to avoid steric
clashes. Such residues will have difficulty maneuvering
within the confines of the bind site and they are expected
to have difficulty adopting different conformations. S-Fil-
ter computes a SA-score (100 minus relative solvent acces-
sibility) that is designed to place greater weight on
residues with low solvent accessibility. The relative sol-
vent accessibility is computed from a crystal structure of a
kinase belonging to the set of inhibited kinases. This
allows S-Filter to incorporate information derived from a
three dimensional structure without requiring a crystal
structure to be solved for all kinases in the selectivity
panel. An alignment column will have a high SA-score
when its residue belonging to the reference structure has a
low solvent accessibility value.
MW-score
Small residues are likely to create a sub-pocket that is not
found in kinases with a bulkier residue at the correspond-
ing position. A bulkier residue is more likely to cause a
steric clash with a nearby substituent. S-Filter computes a
MW-score (the molecular weight of Trp, the largest resi-
due minus the molecular weight of the largest residue in
the set of inhibited kinases). The score is designed such
that small residues will have higher scores. An alignment
column will have a high MW-score when the set of inhib-
ited kinases have small residues and the set of uninhibited
kinases have larger residues at the corresponding position.
C-score
To ensure that all the inhibited kinases remain visible, a
residue filter must specify all residues that are present in
the set of inhibited kinases. This set of residues could
potentially include several different types of residue. In
contrast, specificity determining residues are generally
expected be identical or similar in physical chemical prop-
erties. The Von Neumann entropy conservation score (C-
score) is used to up-weight conserved residues [14]. An
alignment column will have a high C-score when the set
of inhibited kinases have identical or similar residues at
the corresponding position.
Binding sites and residue accessibilities
The tree dimensional structures were used to define the
binding sites and to compute relative residue solvent
accessibilities in PFAAT [15]. Residue accessibilities were
determined for each protein chain in the absence of its
small molecule. The residue accessibilities were used to
compute the SA-score above.
All residues that undergo a relative solvent accessibility
change of 1% or more when bound to the small molecule
of interest are defined as binding site residues. S-Filter
analysis was applied to the alignment columns that corre-
spond to binding site residues for the appropriate small
molecule.
Compound selection
Seven kinase inhibitors (Figure 1) were tested in our
kinase panel (Figure 2). The raw data for the kinase assays
are provided in Additional file 1 and are also available at
http://people.brandeis.edu/~dcaffrey/kinaseSpecificity/.
The seven compounds were chosen because they have
been determined to be selective in other kinase panels
[12,16-18] and their three-dimensional structures have
been solved in complex with a relevant kinase [11,19-24].
To ensure each compound belongs to a distinct chemical
series, we require all compounds to have pair-wise Day-
light® fingerprint [25] Tanimoto scores less than 0.5. For
the purpose of validating the method, it is desirable to
select compounds where the selectivity determinants are
described by independent research groups. Selectivity
determinants were previously described for four of the
seven compounds [11,20,22,24,26]. The PDB codes are
listed in Table 1.
Assessing the predictions
S-Filter predictions were made for all seven compounds
and are summarized in Table 1. To evaluate prediction
accuracy, we compiled a list of residues that were pro-
posed by independent groups to be specificity determi-
nants. After careful examination of three-dimensional
structures, we also concluded that four additional predic-
tions should be treated as true positives. These self-desig-BMC Bioinformatics 2008, 9:491 http://www.biomedcentral.com/1471-2105/9/491
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Small molecule kinase inhibitors analyzed in this work Figure 1
Small molecule kinase inhibitors analyzed in this work.BMC Bioinformatics 2008, 9:491 http://www.biomedcentral.com/1471-2105/9/491
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nated true positive predictions are italicized in table 1 and
are rationalized below. In the absence of supporting data,
the remaining predictions were designated as false posi-
tives. In general, S-Filter does a reasonably good job of
predicting specificity determinants (Table 1). The predic-
tions are evaluated in more detail below.
Kinase selectivity profile
All protein kinase assays (Table 2) were run in a 384-well
format, using either a Caliper protocol [27,28] or a radio-
active protocol [29,30]. Each compound was tested in
duplicate at 1 μM to determine a percent inhibition value.
The enzyme reaction protocol consists of four major steps:
1) 5 μL of 5× concentration of compound in 3.5% DMSO
is added to each plate. 2) 10 μL of 2.5× of kinase enzyme
in 1.25× kinase buffer is added and incubated for fifteen
minutes at room temperature. 3) 10 μL of peptide and
ATP in 1.25× kinase buffer is added to initiate the reac-
tion. The reaction is incubated at room temperature. 4)
The reaction is stopped by the addition of EDTA to a final
concentration of 20 nM.
The kinase buffer is comprised of Hepes, a divalent cation
(Mg2+ or Mn2+), and brij detergent. The concentration of
each substrate was optimized for each kinase individually.
Each assay is run at the Km concentration of ATP for the
Heatmap for the kinase selectivity profile Figure 2
Heatmap for the kinase selectivity profile. Mean percent inhibition data for all compounds (1 μM) run in duplicate, are 
displayed as false colors according to the legend.
Table 1: S-Filter predictions
Compound Primary target PDB Predictions FN FP TN TP Total
SB-203580 p38 1A9U Leu 104 Thr 106 0 0 14 2 16
PHA-00781089 MK2 2P3G Cys 140 Gly 143 0 1 18 1 20
Roscovitine CDK2 2A4L Val 64 Leu 83 Ala 144 02 2 0 12 3
PP1 SRC/HCK 1QCF Thr 338 Gly 344 0 1 18 1 20
OSI-774 EGFR 1M17 Thr 766 Cys 773 0 1 19 1 21
GW-572016 EGFR 1XKK Cys 775 20 2 3 12 6
Fasudil ROCK1 2ESM Val 137 Met 153 Ala 215 1 2 14 1 17
Predicted specificity determinants are shown for each compound and are either designated as false positives (FP) or true positives (TP). Five of the 
predicted residues are in italics as they are self-designated true positives after validating them through structural superposition studies. Residues 
that were not predicted as specificity determinants are not shown but are either designated as false negatives or true negatives. The total number 
of residues in the binding site are shown in the final column.BMC Bioinformatics 2008, 9:491 http://www.biomedcentral.com/1471-2105/9/491
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relevant kinase with an incubation time that is within the
linear reaction time.
For the radiometric assays, tracer amounts of gamma 33P
labeled ATP are included in the reaction. Once the reac-
tions were stopped, they were transferred to Perkin Elmer
Flashplates™. The plates were washed with 50 mM Hepes,
and soaked for one hour in 500 μM unlabeled ATP. The
plates were then re-washed with 50 mM Hepes and read
in a TopCount detector.
For the Caliper mobility shift assay, after the reactions
were stopped, the plates were read on a Caliper LC300
using a 12-sipper chip where separation conditions were
optimized for each kinase. To measure the amount of sub-
strate converted to product, product to sum ratios were
reported.
SB-203580
SB-203580 selectively inhibits EGFR and p38 in the
kinase panel (Figure 2). These two kinases are on distinct
branches of the kinome tree [1] and share relatively low
sequence identity in the binding site. S-Filter predicts that
Leu 104 and Thr 106 are specificity determinants for SB-
203580 (Figure 3). SB-203580 is a well-characterized
compound, and the structural basis for its selectivity at the
gatekeeper position is well known [11,31]. The relatively
small threonine provides access to the so-called selectivity
pocket. For example, ERK2 is not inhibited by SB-203580
as it has a bulkier glutamine at this position. However,
mutation of glutamine 105 to a threonine makes ERK2
susceptible to inhibition by SB-203580 [31]. These exper-
imental observations support the prediction of Thr 106 as
a specificity determinant and we designate the prediction
as a true positive in Table 1.
However, three of the kinases that have a threonine at the
gatekeeper position are not inhibited by SB-203580, indi-
cating that there are additional specificity determinants.
To the best of our knowledge, this is the first time that Leu
104 has been proposed as a selectivity-determining resi-
due. Following this prediction, we explored the conse-
quences of SRC, LCK, and ABL having an isoleucine in
place of Leu 104. When ABL is superposed onto the struc-
ture of p38-SB-203580, the isoleucine of ABL appears to
clash with the fluorophenyl of SB-203580 (Figure 4). In
contrast, Leu 104 of p38 is free to rotate its side chain and
accommodate the fluorophenyl. Based on this putative
Table 2: Kinases in the selectivity panel
Kinase UniProt accession
ABL P00519
AKT P31749
AURA O14965
CDK2 P24941
CHK1 O14757
CKIIa P19138
EGFR P00533
ERK2 P28482
FGFR1 P11362
GSK3b P49841
HGFR P08581
IKKb O14920
IKKi Q14164
IRK P06213
KDR/VEGF P35968
LCK P06239
MK2 P49137
MST4/MASK Q9P289
p38 Q16539
PAK4 O96013
PDK1 O15530
PKAca P17612
PKCb P05771
ROCKI Q13464
SRC P12931
TAO3 Q9H2K8
TRKA P04629
S-Filter results for SB-203580 Figure 3
S-Filter results for SB-203580. S-Filter is available 
through the PFAAT application. Percent inhibition values are 
displayed to the right of the kinase name. S-Filter analysis was 
restricted to alignment columns that correspond to residues 
that make contact with SB-203580. All residues that do not 
make contact with SB-203580 are hidden so that all contact 
resides appear as a contiguous sequence. S-Filter has applied 
filters to the tenth and eleventh columns as indicated by the 
filter boxes above the respective columns. Leucine and thre-
onine are predicted as selectivity determinants, and all unin-
hibited kinases that do not have these residues are hidden by 
the respective filters.BMC Bioinformatics 2008, 9:491 http://www.biomedcentral.com/1471-2105/9/491
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steric clash, we propose that S-Filter correctly predicted
Leu 104 and we self-designate the prediction as a true pos-
itive in Table 1. This prediction demonstrates S-Filter's
ability to flag selectivity determinants that have been over-
looked by previous efforts. In this case, key information
was derived from the multiple sequence alignment. In
summary, the above observations suggest that the two
predictions are correct.
PHA-00781089
PHA-00781089 selectively inhibits MK2 in the kinase
panel (Figure 2). S-Filter predicts Cys 140 and Gly 143 to
be specificity determinants for PHA-00781089. The struc-
ture of PHA-00781089 in complex with MK2 was recently
reported [22]. Anderson et al demonstrated that a similar
compound that lacks the fluorophenyl substituent
potently inhibited CDK2, thus indicating the importance
of this position for selectivity against CDK2. The fluor-
ophenyl interacts with Cys 140 in MK2, whereas the
majority of protein kinases (e.g. CDK2) have a bulkier
side chain at this position. Anderson et al concluded that
a bulkier side chain would lead to a steric clash with the
fluorophenyl of PHA-00781089 (Figure 5). Therefore, the
prediction of Cys 140 as specificity determinant is desig-
nated as a true positive in Table 1.
Gly 143 is at the opening of the binding site and we have
no further evidence to suggest that it is a specificity deter-
minant for PHA-00781089. This prediction is considered
a false positive. Interestingly, S-Filter selected Gly 143 in
its first iteration, and this selection became redundant
when Cys 140 was subsequently selected. In summary, the
experiments described above suggest that one of the two
predictions are correct.
Structural basis for SB-203580 selectivity Figure 4
Structural basis for SB-203580 selectivity. The 3D structure of Abl (PDB 1M52, wire rendering with grey carbons) was 
superposed onto the structure of p38 (hidden) in complex with SB-203580 (PDB 1A9U, ball and stick rendering with green 
carbons). Like p38, Abl has a Thr at the gatekeeper position and suggests that there are other selectivity determinants that 
prevent SB-203580 from inhibiting Abl. The fluorophenyl of SB-203580 appears to clash (orange lines) with Ile 313 (ball and 
stick rendering with grey carbons) of Abl. In contrast, Leu 104 (stick rendering with green carbons) of p38 accommodates the 
compound. Importantly, the isoleucine is deep in the pocket where other isoleucine rotamers are likely to clash with other 
residues in Abl. Based on this putative steric clash, we propose that S-Filter correctly predicted Leu 104 as specificity determi-
nant for Roscovitine.BMC Bioinformatics 2008, 9:491 http://www.biomedcentral.com/1471-2105/9/491
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Roscovitine
Roscovitine selectively inhibits CDK2 in our kinase panel
(Figure 2). The purine ring of Roscovitine is unusual in
that it adopts a different orientation to the purine ring of
ATP. This is due to the benzyl substitution on 6-NH.
Superposing the purine ring of Roscovitine onto ATP sug-
gests that the benzyl ring of Roscovitine would clash with
Phe 80 of CDK2. It is likely that all of the uninhibited
kinases in the panel are able to accommodate the outward
facing benzyl ring. S-Filter predicts that Val 64, Leu 83,
and Ala 144 are specificity-determining residues. Unfortu-
nately, specificity determining residues have not been
experimentally determined for Roscovitine.
To the best of our knowledge, this is the first time that Ala
144 has been proposed as a selectivity-determining resi-
due. When p38 is superposed onto CDK2, Roscovitine
appears to clash with Leu 167 of p38 (Figure 6). This puta-
tive steric clash suggests that a bulkier residue in place of
Ala 144 will not accommodate Roscovitine. Based on this
putative steric clash, we propose that S-Filter correctly pre-
dicted Ala 144 and we self-designate the prediction as a
true positive in Table 1. The remaining predictions are
regarded as false positives. In summary, the above obser-
vations suggest that one of the three predictions are cor-
rect.
PP1
PP1 is selectively inhibits SRC, LCK, EGFR, and ABL in our
kinase panel (Figure 2). The three-dimensional structure
of PP1 was solved in complex with HCK. We refer to HCK
numbering in the text below. S-Filter predicts Thr 338 and
Gly 344 as specificity determinants. Schindler et al
describe Thr 338 as a specificity-determining residue for
PP1 [20]. Liu et el demonstrated that a single residue dif-
ference at position 338 could account for the differences
in potency observed between SRC and v-SRC [32]. By
mutating Ile 338 to different residue types, including thre-
Structural basis for PHA-00781089 selectivity Figure 5
Structural basis for PHA-00781089 selectivity. The 3D structure of CDK2 (PDB 2A4L, wire rendering with grey car-
bons) was superposed onto the structure of MK2 (hidden) in complex with PHA-00781089 (PDB 2P3G, ball and stick render-
ing with green carbons). Anderson et al [22] demonstrated that the fluorophenyl of PHA-00781089 provided selectivity against 
CDK2 as a compound without this substituent was a potent inhibitor of CDK2. Consistent with this observation, the fluoroph-
enyl of PHA-00781089 makes a number of clashes (orange lines) with Phe 82 (stick rendering with grey carbons) of CDK2, 
whereas Cys 140 (stick with green carbons) of MK2 accommodates the inhibitor. We therefore conclude that S-Filter cor-
rectly predicted Cys 140 as a specificity determinant.BMC Bioinformatics 2008, 9:491 http://www.biomedcentral.com/1471-2105/9/491
Page 10 of 15
(page number not for citation purposes)
onine, they demonstrated that the presence of a small res-
idue was necessary for potent inhibition by PP1. Liu et al
concluded that kinases with a bulkier residue at position
338 will clash with PP1 (Figure 7). These experimental
observations support the prediction of Thr 338 as a specif-
icity determinant and we designate the prediction as a true
positive in Table 1.
We could not find any evidence to suggest that Gly 344 is
a specificity determinant for PP1, and this prediction is
designated as a false positive. However, Thr 338 cannot be
the only specificity determinant, as p38 is not inhibited by
PP1, despite having a threonine at the gatekeeper posi-
tion. As PP1 is small and does not probe deeply into the
selectivity pocket, it is possible that it does not form high-
affinity interactions with the corresponding p38 residues.
In summary, the experiments described above suggest that
one of the two predictions are correct.
OSI-774/CP-358774
OSI-774 selectively inhibits EGFR and ABL in our kinase
panel (Figure 2). S-Filter predicts Thr 766 and Cys 773 to
be selectivity determinants for OSI-774. Unfortunately,
Stamos et al do not explicitly describe specificity determi-
nants for OSI-774 [21].
Although OSI-774 does not access the so called specificity
pocket that lies beyond Thr 766, the presence of a bulkier
residue may prevent inhibition. For example, when CHK1
is superposed onto EGFR, OSI-774 appears to clash with
Leu 84 of CHK1 (Figure 8). This putative steric clash sug-
gests that a bulkier residue in place of Thr 766 will not
accommodate OSI-774. Based on this putative steric
clash, we propose that S-Filter correctly predicted Thr 766
and we self-designate the prediction as a true positive in
Table 1. As Cys 773 is at the opening of the binding site,
it is not clear how it could be specificity-determining, and
it is designated as a false positive. This false positive high-
lights the shortcomings of S-Filter and the need to care-
Structural basis for Roscovitine selectivity Figure 6
Structural basis for Roscovitine selectivity. The 3D structure of p38 (PDB 2GTM, wire rendering with grey carbons) was 
superposed onto the structure of CDK2 (hidden) in complex with Roscovitine (PDB 2A4L, ball and stick rendering with green 
carbons). Roscovitine appears to clash (orange lines) with Leu 167 (ball and stick rendering with grey carbons) of p38. Impor-
tantly, Leu 167 is buried deep in the pocket where there is little room to maneuver. In contrast, Ala 144 (stick rendering with 
green carbons) of CDK2 accommodates the compound. Based on this putative steric clash, we propose that S-Filter correctly 
predicted Ala 144 as specificity determinant for Roscovitine.BMC Bioinformatics 2008, 9:491 http://www.biomedcentral.com/1471-2105/9/491
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fully assess all predictions before proceeding. In
summary, the above observations suggest that one of the
two predictions is correct.
GW-572016
GW-572016 selectively inhibits EGFR in our kinase panel
(Figure 2). S-Filter predicts Cys 775, as a specificity deter-
minant for GW-572016. Wood et al do not explicitly
describe specificity determinants for GW-572016[23]. To
the best of our knowledge, this is the first time that Cys
775 has been proposed as a selectivity-determining resi-
due. When p38 is superposed onto EGFR, GW-572016
appears to clash with Ile 84 of p38 (Figure 9). This puta-
tive steric clash suggests that many of the kinases in our
panel with a bulkier residue in place of Cys 775 will not
accommodate GW-572016. In contrast, cysteine has a
non-branched side chain that presumably allows it to
rotate and accommodate GW-572016. Based on this puta-
tive steric clash, we propose that S-Filter correctly pre-
dicted Cys 775 and we self-designate the prediction as a
true positive in Table 1
S-Filter failed to predict Thr 790, which provides access to
the selectivity pocket. S-Filter also failed to predict Met
766 which may provide additional specificity through its
flexible side chain. Additionally, the C helix of EGFR has
moved away from the binding site to accommodate GW-
572016, suggesting that selectivity extends to other parts
of the protein that do not directly contact GW-572016. As
S-Filter does not consider conformational changes, it is
recommended that S-Filter analysis is combined with
structural comparisons whenever possible. In summary,
the above observations suggest that S-Filter correctly pre-
dicted one specificity determinant, but also failed to pre-
dict two other specificity determinants.
Structural basis for PP1 selectivity Figure 7
Structural basis for PP1 selectivity. The 3D structure of CDK2 (PDB 2A4L, wire rendering with grey carbons) was super-
posed onto the structure of HCK (hidden) in complex with PP1 (PDB 1QCF, ball and stick rendering with green carbons). PP1 
makes a number of clashes (orange lines) with Phe 80 (ball and stick rendering with grey carbons) of CDK2 whereas Thr 338 
(stick rendering with green carbons) of HCK accommodates the compound. By mutating the threonine to a bulkier residue, 
Liu et el demonstrated that this position was an important specificity determinant for PP1[32]. We therefore conclude that S-
Filter correctly predicted Thr 338 as a specificity determinant.BMC Bioinformatics 2008, 9:491 http://www.biomedcentral.com/1471-2105/9/491
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Fasudil
Fasudil selectively inhibits ROCK1 in our kinase panel
(Figure 2). Structural and mutational studies implicate Ala
215 along with Ile 82 as selectivity determinants [24,26].
Bonn et al demonstrated that Fasudil is not a potent inhib-
itor of PKA. By mutating Thr 183 in PKA to the corre-
sponding position in Rock (Ala 215), they demonstrated
that Fasudil inhibited the mutant PKA at levels similar to
ROCK. Similarly, by mutating Leu 49 in PKA to the corre-
sponding residue in ROCK (Ile 82), they observed inhibi-
tion levels similar to wild type ROCK. Figure 10 suggests
a slightly bulkier threonine in place of Ala 215 could pre-
vent Fasudil from binding deep in the active site. Based on
these experimental observations, we designate Ala 215 as
a true positive in Table 1. S-Filter failed to predict Ile 82
and we designate it as a false negative in Table 1. S-Filter
also predicted Val 137 and Met 153 as specificity determi-
nants for Fasudil. We designate both of these predictions
as false positives. In summary, the above observations
suggest that one of the three predictions are correct.
Discussion and Conclusion
S-filter is a hypothesis generation tool that flags potential
selectivity determinants for further structural analysis or
experimentation. The method relies on selectivity data, a
multiple sequence alignment and parameters derived
from the three dimensional structure of a kinase in com-
plex with the compound of interest. Unlike similarity
metrics that summarize multiple residue positions with a
single metric (e.g. percent identity), S-Filter evaluates each
residue position independently. This is important as spe-
cificity can often be attributed to a single-residue differ-
ence. By incorporating solvent accessibility data from the
crystal structure, S-Filter tends to favor the prediction of
specificity determinants that are deep in the pocket of the
active site. This reduces the likelihood of S-Filter converg-
ing towards residue positions that are solvent exposed and
less likely to be specificity determinants.
Analysis is restricted to residues that make contact with
the compound, and S-Filter does not consider other resi-
dues that may exert their effects indirectly or through con-
Structural basis for OSI-774 selectivity Figure 8
Structural basis for OSI-774 selectivity. The 3D structure of CHK1 (PDB 2BRH, wire rendering with grey carbons) was 
superposed onto the structure of EGFR (hidden) in complex with OSI-774 (PDB 1M17, ball and stick rendering with green car-
bons). OSI-774 appears to clash (orange lines) with Leu 84 (ball and stick rendering with grey carbons) of CHK1, whereas Thr 
766 (stick rendering with green carbons) of EGFR accommodates the compound. Based on these putative steric clashes, we 
propose that S-Filter correctly predicted Thr 766 as a specificity determinant.BMC Bioinformatics 2008, 9:491 http://www.biomedcentral.com/1471-2105/9/491
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formational changes, e.g. the DFG loop. Alternative
binding modes [33] are not explicitly modeled, and at
best S-Filter could only predict multiple specificity deter-
minants for such cases. The presence of key interacting
waters will not be explicitly taken into account. However,
it is conceivable that S-Filter could detect a residue that
indirectly interacts with the compound via a specific
water-mediated hydrogen bond. S-Filter uses a greedy
algorithm to filter for specificity determinants and has the
potential to commit to a path that does not lead to the
optimal prediction. The predictions made for Roscovitine
and OSI-774 reveal some of the pitfalls associated with S-
Filter. Fortunately, these predictions were easily dismissed
after inspecting the structure.
Despite these potential shortcomings, S-Filter made a
number of useful predictions that either agreed with prior
experimental data or were supported by structural super-
position studies. Prior experimental data was available for
four of the seven compounds, and in each case S-Filter
correctly predicted at least one specificity determinant
(Table 1). S-Filter also made a number of novel predic-
tions for SB-203580, Roscovitine, OSI-774 and GW-
572016. These predictions point to potential selectivity
determinants that appear plausible and await experimen-
tal validation. Furthermore, these predictions demon-
strate the ability of S-Filter to find subtle trends that are
not readily detected. Overall, eight of the fifteen predic-
tions are regarded as true positives. However, it is impor-
tant that these metrics are not interpreted as an indicator
of prediction accuracy, as our validations are limited to a
small number of compounds. Nevertheless, the predic-
tions are encouraging, as the challenges associated with
rationalizing inhibitor selectivity are both difficult and
time-consuming. S-Filter assists this process by prioritiz-
ing residues for further structural analysis and follow-up.
In instances where the selectivity can be rationalized, one
might consider mutagenesis studies or compound modi-
fications to further optimize or abrogate selectivity.
Structural basis for GW-572016 Figure 9
Structural basis for GW-572016. The 3D structure of p38 (PDB 1A9U, wire rendering with grey carbons) was superposed 
onto the structure of EGFR (hidden) in complex with GW-572016 (PDB 1XKK, ball and stick rendering with green carbons). 
GW-572016 appears to clash (orange lines) with Ile 84 (ball and stick rendering with grey carbons) of p38. In contrast, Cys 775 
(stick rendering with green carbons) of EGFR accommodates the compound. Importantly, Ile 84 is buried deep in the protein 
where there is little room to maneuver and clearly protrudes the pocket (mustard) of EGFR. Based on this putative steric 
clash, we propose that S-Filter correctly predicted Cys 775 as specificity determinant for GW-572016.BMC Bioinformatics 2008, 9:491 http://www.biomedcentral.com/1471-2105/9/491
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